We are live on ! Find out more
AIIC

AJU IB Investment Company Portfolio holdings

AUM $30.5M
1-Year Est. Return 128.96%
This Fund
S&P 500
This Quarter Est. Return
+13.61%
1 Year Est. Return
+128.96%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$91.9M
AUM Growth
+$7.84M
Cap. Flow
-$8
Cap. Flow %
-0%
Top 10 Hldgs %
100%
Holding
8
New
Increased
Reduced
1
Closed

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
RAPT
RAPT Therapeutics
RAPT
+$8

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ACLX
1
DELISTED
Arcellx
ACLX
$69M 75.07%
1,047,557
KYMR icon
2
Kymera Therapeutics
KYMR
$8.94B
$19.9M 21.71%
457,059
SEER icon
3
Seer Inc
SEER
$120M
$1.75M 1.9%
816,375
XLO icon
4
Xilio Therapeutics
XLO
$60.3M
$454K 0.49%
47,696
CARM
5
DELISTED
Carisma Therapeutics
CARM
$281K 0.31%
718,332
RLYB icon
6
Rallybio
RLYB
$85.8M
$255K 0.28%
94,335
STRO icon
7
Sutro Biopharma
STRO
$421M
$125K 0.14%
17,500
RAPT
8
DELISTED
RAPT Therapeutics
RAPT
$99.5K 0.11%
12,437
-1
-0% -$8

Similar funds

AJU IB Investment Company's Q2 2025 Portfolio in Review

As of Q2 2025, AJU IB Investment Company held 8 positions worth $91.9M, up 9.3% from $84M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2025: portfolio turnover was 0%. AJU IB Investment Company opened no new positions and made no exits, leaving the 8-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • AJU IB Investment Company's biggest Q2 2025 reduction was RAPT Therapeutics, cutting an estimated $8.
  • AJU IB Investment Company's ten largest holdings make up 100% of its $91.9M portfolio in Q2 2025.
  • AJU IB Investment Company opened 0 new positions and closed 0 in Q2 2025.
  • AJU IB Investment Company's portfolio value rose 9.3% quarter-over-quarter to $91.9M.

Based on AJU IB Investment Company's 13F filing for Q2 2025, filed 10 Jul 2025.